ARTICLE | Tools & Techniques
Breaking the barrier
Companies are finally finding ways to develop cell-penetrating biologics
June 15, 2017 11:34 PM UTC
A three-way deal between Amgen Inc., Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics.
The biotechs join a small but growing cohort of companies creating protein-based therapeutics that can cross the plasma membrane to reach intracellular targets - a challenge that has plagued the field almost since the dawn of the industry...